Only one company, Pfizer, has been granted a license to manufacture and distribute an FDA approved COVID vaccine. Pfizer’s FDA licensed vaccine must be labelled “Comirnaty” and include licensing information. To date, Pfizer has not allowed distribution of “Comirnaty” in the United States.
Liability is not the issue. Regardless of whether or not a vaccine is distributed under full FDA license or Emergency Use Authorization (EUA), the manufacturer still enjoys liability immunity thanks to the National Childhood Vaccine Injury Act of 1986 as well as subsequent legislation further strengthening legal protections for drug makers. Yet there are very important differences when it comes to compensation programs for vaccine related injuries between EUA and FDA licensed products
Here’s what everyone should know:
There are two distinct government administered programs that can pay compensation to individuals for vaccine related injuries or death. The program that administers claims/compensation for an EUA vax is called the “Countermeasures Injury Compensation Program” (CICP).
The CICP is a fully government funded program. Drug manufacturers are required to pay nothing into this fund. Claims for medical expenses sustained by a vaccine administered under EUA are evaluated by the Health Resources & Services Administration. Benefits are limited to the “un-insured” and/or certain medical expenses not covered by other insurance and/or lost employment. (See eligibility requirements for filing claims on the CICP website).
“The U.S. Department of Health and Human Services is the payer of last resort, which means CICP covers what remains unpaid or unpayable by other third parties, e.g., health insurance. If eligible, you may be compensated for:
Medical Expenses. The unreimbursed medical items or services used to treat a covered countermeasure injury may qualify for reimbursement. Please Note: These items and services must be reasonable and necessary, and not fully paid or reimbursed by insurance or government programs such as Medicaid or Veterans Benefits.
Lost Employment Income: If you were unable to work because of a covered countermeasure injury, you may qualify for lost employment income. Please Note: You must have been unable to work for more than 5 days to receive benefits.”https://www.hrsa.gov/cicp/types-of-benefits
When it comes to an injury from an FDA licensed vaccine, compensation is provided through the “Vaccine Injury Compensation Program” (VICP). The VICP is a public Trust Fund under the jurisdiction of the U.S. Treasury and is funded by an excise tax of $.75 cents per dose for any FDA licensed vaccine as required by the aforementioned National Childhood Vaccine Injury Act of 1986. This per dose tax is collected from the vaccine manufacturer and paid to the U.S. Treasury.
From the HRSA website:
“The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury petitions. It was created in the 1980s, after lawsuits against vaccine companies and health care providers threatened to cause vaccine shortages and reduce U.S. vaccination rates, which could have caused a resurgence of vaccine preventable diseases. Any individual, of any age, who received a covered vaccine and believes he or she was injured as a result, can file a petition. Parents, legal guardians and legal representatives can file on behalf of children, disabled adults, and individuals who are deceased.”
Individuals injured by a fully approved FDA licensed vax, or their family members or legal representatives, can file a petition to the VICP resulting in an award of up to $250,000 for a vaccine related injury or death. The VICP is also known as “Vaccine Court” because plaintiffs may actually bring in witnesses and present testimony before a judge to substantiate or validate their claims. The VICP allows claims to be filed up to 2 to 4 years after vaccination and is not dependent on employment or insurance status. Whereas, the CICP has a one year filing deadline and only covers lost wages and medical expenses AFTER ALL OTHER INSURANCE AND/OR EMPLOYMENT BENEFITS ARE EXHAUSTED!
Pfizer is saving tens of millions of dollars in excise taxes by continuing to distribute their vaccine under EUA. Likewise, individuals harmed by the current EUA vax are not eligible to file a compensation claim to the VICP. After all, no one can be harmed by an FDA approved vaccine that no one has received.
By avoiding distribution of the FDA licensed vaccine, (which must be labelled “Comirnaty” and include licensing information), Pfizer also avoids a lot of negative publicity. Judging by the number of serious adverse reactions reported to the VAERS website, the VICP Trust Fund would quickly become exhausted if even a small percentage of VAERS claims proved legitimate. There simply isn’t enough money in the fund to cover the anticipated flood of injury claims.
Understanding the differences between the injury compensation programs is critical in understanding how we are being played for fools. Don’t believe me? Call your local pharmacy or health care provider and ask if they are administering the FDA licensed COVID vaccine. When they say, “Yes, we are administering the Pfizer vaccine, which is FDA approved”, ask them to prove it by providing you with FDA licensing and labelling information. Odds are, they won’t even know what you are talking about.
Sources for this article include:
- “Pfizer received FDA BLA license on 8/23/2021 for its COVID-19 vaccine for use in individuals 16 and older (COMIRNATY). At that time, the FDA published a BLA package insert that included the approved new COVID-19 vaccine tradename COMIRNATY and listed 2 new NDCs (0069-1000-03, 0069-1000-02) and images of labels with the new tradename. At present, Pfizer does not plan to produce any product with these new NDCs and labels over the next few months while EUA authorized product is still available and being made available for U.S. distribution. As such, the CDC, AMA, and drug compendia may not publish these new codes until Pfizer has determined when the product will be produced with the BLA labels.” https://dailymed.nlm.nih.gov/dailymed/dailymed-announcements.cfm